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Dimethylamine borane [DMAB, dimethy-
lamine-borane complex; (CH3)2NHBH3, CAS
no. 74-94-2] is a strong reducing agent and is
an important chemical in the semiconductor
industry (Jagannathan and Krishnan 1993).
DMAB is a white, crystalline solid with a mole-
cular weight of 58.92 g/mol and melting point
of 33–36°C. The chemical structure of DMAB
is shown in Figure 1 (BASF 2004). 
DMAB is toxic and hazardous to the
environment (BASF 2004). It is an irritant
and is corrosive to the skin and mucosa
(BASF 2004). However, to our knowledge,
there have been no published reports, to date,
of human exposure. Here we report a case of
occupational DMAB exposure that caused
signiﬁcant neurotoxicity. We also found three
other cases of occupational DMAB exposure
during our ﬁeld investigation.
Case Presentation
A 36-year-old, healthy male was accidentally
sprayed over the face and trunk with the liquid
form of DMAB (Figure 2). He kept on work-
ing and did not take a shower until > 1 hr
later. He developed dizziness, nausea, vomit-
ing, sore throat, limb numbness, slurred
speech, slow motion, lack of concentration,
and ataxia by the next morning, 13 hr after
exposure. He was admitted to a local hospital,
where a normal brain computerized tomogram
was noted. Because of worsening clinical con-
ditions, including “masked” face, irritability,
awkwardness, and rocking from side to side
while sitting on the bed, he was transferred to
our hospital 3 days later. Physical examination
revealed some abnormal neurologic ﬁndings.
The patient was oriented as to time and place
but was easily distracted. His speech was
slurred. Normal muscle power was noted for
all four limbs. He could stand on a wide base
with assistance but deviated to both sides when
attempting a tandem gait. Impairment on ﬁn-
ger-to-nose and heel-to-knee tests was also
noted. He denied any medical problems such
as hypertension, diabetes, and neurologic dis-
eases. He smoked one pack of cigarettes per
day and drank alcohol occasionally. 
A routine laboratory work-up including
complete blood cell count, electrolytes, blood
sugar, and hepatic and renal function tests was
performed. Mild hyperventilation, with arterial
blood gas of pH 7.510, partial pressure of car-
bon dioxide 30.6 mm Hg, partial pressure of
oxygen 100 mm Hg, and bicarbonate
24.7 mmol/L, was found. No drug history,
including use of herbal medicine, was noted
for the last 3 months. Urinalysis did not detect
any illegal drugs, central nervous system-acting
drugs, or other medications. Normal blood
and urine lead, mercury, and aluminum levels
were also noted. 
Eight days after chemical exposure, the
patient’s electroencephalogram (EEG)
revealed diffuse background slowing, indica-
tive of a mild diffuse cerebral dysfunction.
Tests of nerve conduction velocity (NCV) for
the left-side limbs were normal. Brain mag-
netic resonance imaging (MRI) on the eighth
day showed a symmetric increase in signal
intensity on FLAIR (fluid-attenuated inver-
sion recovery), T2WI (T2-weighted inten-
sity), and DWI (diffusion-weighted images),
but low signal intensity on T1WI without
postcontrast enhancement at bilateral cerebel-
lar periventricular areas (Figure 3A). A steroid
was prescribed for treatment of the possible
acute inflammatory effects on neurons. The
patient was discharged with stable neurologic
function after 6 days of observation.
The pateint was readmitted to our neu-
rology outpatient clinic 18 days after chemi-
cal exposure due to difﬁculty in walking and
climbing. Physical examination revealed that
the deep tendon reflexes of both knees were
areﬂexic. Muscle power was mildly decreased
in the distal and proximal parts of the upper
right leg. Lower leg weakness and drop foot
were also found bilaterally with muscle power
of grade 2/5 in the right foot and 3/5 in the
left foot. A nerve conduction study on the
29th day after poisoning showed decreased
NCV and complex muscular action potential
(CMAP) amplitudes for the left median, left
ulnar, left peroneal, and left tibial nerves.
H-reﬂex was absent bilaterally. Sensory con-
duction and sensory evoked potential tests of
the nerves of the upper left and lower left
limbs were normal. A brain MRI on the 37th
day after poisoning showed that the previous
lesions in the cerebellar dentate nuclei region
had subsided (Figure 3B).
With active physical therapy, the patient
could walk straight on a wide base 2 months
after poisoning. No dysmetria was noted on
the ﬁnger-to-nose test, but heel or toe gait was
impaired. The muscle power was grade 3/5 in
the ﬂexor and extensor of the right foot; 4/5
in the ﬂexor and extensor of the left foot, and
others were all 5/5. Weakness in the flexor
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CONTEXT: Dimethylamine borane (DMAB) is a reducing agent used in nonelectric plating of
semiconductors. Exposures are usually through occupational contact. We report here four cases of
people who suffered from work-related exposure to DMAB. 
CASE PRESENTATION: Three patients exposed to DMAB decontaminated immediately by drinking a
lot of water; they reported dizziness, nausea, diarrhea 6–8 hr later. The other patient did not decon-
taminate at once, and he suffered from more severe symptoms, including dizziness, nausea, limb
numbness, slurred speech, irritable mood, and ataxia 13 hr later. Magnetic resonance imaging
showed symmetric lesions with hyperintensity on T2WI and FLAIR in bilateral cerebellar dantate
nuclei. This patient was readmitted to the hospital due to difficulty in walking and climbing
18 days after exposure. Lower leg weakness and drop foot were found bilaterally. A nerve conduc-
tion study revealed polyneuropathy with motor-predominant axonal degeneration. This patient
receives regular outpatient followups and still walks with a clumsy gait and has difficulty with
hand-grasping activity. 
DISCUSSION: This case study demonstrates that DMAB is highly toxic to humans through any
route of exposure, and dermal absorption is the major route of neurotoxicity. DMAB induces acute
cortical and cerebellar injuries and delayed peripheral neuropathy. 
RELEVANCE: Further investigation of the toxic mechanism of DMAB is warranted. Early decontami-
nation with copious water is the best current treatment for exposure to DMAB.
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Figure 1. Chemical structure of DMAB
[(CH3)2NHBH3] (BASF 2004).
Research | Environmental Medicineand extensor of both feet still remained. A
repeat EEG was normal. A repeat NCV study
revealed no change in polyneuropathy with
motor predominant axonal degeneration. The
patient receives regular outpatient followups.
He still walks with a clumsy gait and has difﬁ-
culty with hand-grasping activity. 
Field Investigation
We performed a field investigation to study
the character and mechanism of chemical
exposure. According to the statement of the
facility manager, the factory produces only
DMAB. The liquid sprayed on the patient
was 97% DMAB. The other 3% was decom-
posed materials including boric acid, borates,
hydrogen, and dimethylamine (DMA).
DMAB was the only toxic substance at the
workplace. 
There were three other workers with a
history of DMAB contamination. Their data
are summarized in Table 1 (cases 2–4). They
all suffered from minor intoxication without
any residual neurologic sequelae.
Discussion
To our knowledge, the human toxicity of
DMAB has never been reported in the litera-
ture. In the BASF material safety data sheet,
DMAB is noted to be toxic and hazardous to
the environment (BASF 2004). It is harmful if
swallowed or absorbed through the skin. Both
vapor and solid can cause eye, skin, and respira-
tory tract irritation. Studies of animals exposed
to high doses of DMAB have demonstrated
injury to the kidneys, liver, adrenals, lungs, and
central nervous system (BASF 2004). Our
patients reveal that DMAB is highly toxic to
humans through any route of exposure. The
major route of toxicity is dermal absorption.
Gastrointestinal symptoms occur the first
6–12 hr after exposure, but the toxicity of
DMAB seems to be limited if prompt deconta-
mination is performed immediately after expo-
sure. Delayed decontamination after DMAB
exposure in our patient did lead to severe toxic-
ity, including acute cerebral and cerebellar dys-
function and delayed polyneuropathy. The
cerebral and cerebellar toxicity of DMAB was
temporary, as evidenced in the patient’s serial
MRI and EEG examinations and clinical mani-
festations. The mechanism of central nervous
system lesions is unknown, but from the study
of serial MRI, transient demyelination, axonal
degeneration, or neuron damage might be sug-
gested (Bradley 1986). According to the clinical
neurologic manifestations and EEG upon
admission, we also suggest that some cortical
dysfunction may have been induced by
DMAB, though it was a negative finding on
the image study 8 days after exposure.
Delayed peripheral neuropathy was the
second important presentation in this case of
DMAB poisoning. The decreased muscle
power of the four limbs developed progres-
sively during the 3 weeks after DMAB expo-
sure. We verified the polyneuropathy with
axonal degeneration by serial EEG/NCV
studies. 
DMAB easily decomposes to boric acid,
borates, hydrogen, and DMA (BASF 2004).
DMA is also toxic by inhalation, ingestion, and
intravenous routes. Gases or vapors from aque-
ous solutions may cause irritation, conjunctivi-
tis, and corneal damage. Inhalation may cause
coughing, nausea, and pulmonary edema
[American Conference of Government
Industrial Hygienists (ACGIH) 1991], but no
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Table 1. Data of four male workers exposed to DMAB.
Case Age Symptom
no. (years) Route of entry Decontamination onset time Symptoms Subside/sequelae
1 36 Sprayed on the face and head Not immediately (1 hr later) 12 hr Altered consciousness, irritable, had difﬁculty walking Symptoms persisted
and climbing, dizziness, slurred speech, limb 
numbness, nausea, vomiting, gastrointestinal upset
2 32 Sprayed over the whole body Took a shower immediately 6 hr Dizziness, nausea, vomiting, and had diarrhea 3 times Symptoms subsided
the next morning
3 28 Ate a particle of DMAB with rice meal Drank a lot of water immediately 6 hr Dizziness, nausea, vomiting, and had diarrhea 5 times Recovered 1 day later













Figure 2. Diagram showing how the patient was exposed to DMAB during the production process. A, Tank
where DMAB is produced. B, container holding DMAB product; one of the screws on the lid of the con-
tainer came loose, and liquid DMAB sprayed out over the face, head, and trunk of the worker. 
Figure 3. MRIs of the patient. (A) Symmetric increase in signal intensity at bilateral cerebellar periventricular
area on T2WI (9 February 2004). (B) Previous cerebellar dantate nuclei region hyperintensity on T2WI has
subsided (17 March 2004).
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systemic effects of DMA intoxication from
industrial exposure have been reported
(Ballantyne et al. 1985). Boric acid is well
absorbed through the gastrointestinal tract,
open wounds, and serous cavities. It causes
gastrointestinal symptoms (nausea, vomiting,
and diarrhea) and dermal effects (erythema,
desquamation). The central nervous system
effects are less common in intoxication by boric
acid in adults. Boric acid causes headache,
lethargy, restlessness, weakness, and seizure, but
cerebellar lesions have not been reported
(Kiesche-Nesselrodt and Hooser 1990; Locatelli
et al. 1987; Mack 1984; Siegel and Wason
1986; Von Burg 1992). Hydrogen is usually
nontoxic when inhaled, but it can displace oxy-
gen, leading to oxygen deﬁciency in a conﬁned
space. In a rat study, repeated administration of
DMAB produced rather severe central nervous
system lesions (BASF 2004). The liquid or
vapor form of DMAB, in concentrations of
≥ 97%, might be a reason for central and
peripheral neurotoxicity.
Conclusion
DMAB intoxication can lead to acute cortical
and cerebellar lesions and delayed polyneu-
ropathy. Early and prompt decontamination
is indicated in an occupational setting.
Further research is needed regarding the
mechanism of DMAB poisoning. 
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